Dawn Martello

Science

Moderna and Merck's vaccine plus pembrolizumab cut the two-year risk of recurrence or death by 42% versus pembrolizumab alone.

2201234567890123456789

NS

SA

DM

4 Sources, 5d ago, updated 5d ago